Literature DB >> 26793558

Some Renal Masses Did Not "Read the Book": A Case of a High Grade Hybrid Renal Tumor Masquerading as a Renal Cyst on Non-contrast Imaging.

Hal D Kominsky1, Daniel C Parker2, Dharam Gohil2, Rachel Musial3, Kristin Edwards4, Alexander Kutikov2.   

Abstract

Hybrid renal tumors (HRT) are rare neoplasms that contain both benign and malignant components. Sporadic solitary HRT that contain high-grade malignant pathology appear to be extremely rare [1]. We describe a case at our institution of a tumor that was characterized as a type-2 papillary RCC and atypical oncocytoma hybrid that mimicked a simple cyst on non-contrast computed tomography.

Entities:  

Keywords:  Attenuation; Hybrid renal tumor; RCC

Year:  2015        PMID: 26793558      PMCID: PMC4714308          DOI: 10.1016/j.eucr.2015.08.001

Source DB:  PubMed          Journal:  Urol Case Rep        ISSN: 2214-4420


Introduction

The incidence of HRT ranges between 1–17% at surgical extirpation.1, 2, 3 Risk of harboring malignant pathology adjacent to a benign tumor component has significant implications for critical decision-making that surrounds percutaneous renal mass biopsy (RMB). Here we present a case of a collision tumor that contained components of type-2 papillary RCC and an atypical oncocytoma. Moreover, on non-contrast computed tomography, the lesion masqueraded as a Bosniak I renal cyst.

Case presentation

A 73-year-old male with history of stable stage 3 chronic kidney disease was referred to our center for evaluation of a right renal mass. The patient was found to have a 3.1 cm enhancing exophytic solid renal mass (R.E.N.A.L. Nephrometry Score 1 + 1 + 1 + x + 2 = 5x) (Fig. 1) on an MRI that was obtained during a work-up of gross hematuria. The patient elected to proceed with a short period of active surveillance and a restaging non-contrast CT of the chest/abdomen/pelvis was obtained to establish tumor growth kinetics. On non-contrast CT, the tumor exhibited attenuation of <5 Hounsfield Units (HU), a finding most consistent with a Bosniak I renal cyst (Fig. 2). The patient elected for transperitoneal robotic partial nephrectomy. Final pathology demonstrated a predominantly oncocytic neoplasm consistent with atypical oncocytoma that contained a microscopic focus of type-2 papillary renal cell carcinoma (Fig. 3).
Figure 1

Axial T1-weighted pre-contrast (A, left) and post-contrast (B, right) MR image at initial presentation. Right renal mass measured 3.1 × 2.4 × 2.4 cm and its anatomic complexity was characterized by an R.E.N.A.L. Nephrometry Score of 1 + 1 + 1 + x + 2 = 5x (arrow).

Figure 2

On non-contrast CT image the tumor masqueraded as a Bosniak I renal cyst.

Figure 3

Tumor histopathology demonstrating an oncocytic neoplasm, favored to be an atypical oncocytoma with abundant eosinophilic granular cytoplasm and small nuclei (white arrow) with concomitant components of Type-2 papillary renal cell carcinoma with large nuclei, prominent nucleoli, and a psammoma body (black arrow).

Discussion

HRTs composed of both benign renal oncoctyoma (RO) and RCC pathology are rare (∼5%) in patients without hereditary syndromes who present with solitary sporadic renal masses.1, 2, 3 In a recent report from our institution, which included nearly 150 benign renal masses, none contained coexisting high-grade tumor components. Nonetheless, reports of high-grade malignant pathology in an HRT do exist. Yet, to our knowledge, there has only been one previous report of a hybrid tumor containing a component of papillary RCC. Furthermore, to our knowledge, this is the first published report of an HRT masquerading as a simple renal cyst on non-contrast imaging. Renal incidentalomas are frequently discovered on CT. Indeed, unenhanced CT is increasingly utilized in the diagnosis of a variety of ailments. The finding of a renal lesion on such imaging poses a specific challenge, as contrast is unavailable to elucidate a lesion's vascularity or internal architecture. Several guidelines have been proposed regarding which lesions identified on non-contrast imaging require further evaluation. O'Connor and colleagues used an indeterminate range of 20-70 HU to predict malignant pathology within renal lesions with 100% sensitivity and 89.4% specificity. Importantly, a validation study confirmed that no malignant lesions in a series of 193 renal masses exhibited HU <20 on unenhanced CT. Nevertheless, heterogeneity of attenuation within renal masses exists, and pre and post-contrast imaging should be undertaken for masses with focal areas of indeterminate attenuation on non-contrast CT even if the majority of the tumor is <20 HU. Indeed, on careful analysis of pre-contrast CT imaging for our patient's lesion, areas of attenuation between 20–70 HU were present. As such, this case underscores that careful assessment of attenuation of the entire lesion on non-contrast CT imaging is important for accurate characterization.

Conclusions

Hybrid renal tumors are rarely occurring neoplasms composed of both benign renal oncocytic features and RCC pathology. However infrequent, the existence of high-grade, malignant RCC pathology in HRT appears to be a clinical reality. We report the first case of an HRT with a type-2 papillary RCC component that masqueraded as a simple renal cyst on unenhanced CT. Steadfast consideration to the attenuation of the entire mass is thus critical in determining risk of malignancy for renal lesions identified on unenhanced CT.

Conflicts of interest

None of the authors of this manuscript reported any conflicts of interest.
  8 in total

Review 1.  Renal mass biopsy--a renaissance?

Authors:  Brian R Lane; Mary K Samplaski; Brian R Herts; Ming Zhou; Andrew C Novick; Steven C Campbell
Journal:  J Urol       Date:  2007-11-13       Impact factor: 7.450

2.  Coexisting hybrid malignancy in a solitary sporadic solid benign renal mass: implications for treating patients following renal biopsy.

Authors:  Serge Ginzburg; Robert Uzzo; Tahseen Al-Saleem; Essel Dulaimi; John Walton; Anthony Corcoran; Elizabeth Plimack; Reza Mehrazin; Jeffrey Tomaszewski; Rosalia Viterbo; David Y T Chen; Richard Greenberg; Marc Smaldone; Alexander Kutikov
Journal:  J Urol       Date:  2013-07-27       Impact factor: 7.450

3.  Incidental finding of renal masses at unenhanced CT: prevalence and analysis of features for guiding management.

Authors:  Stacy D O'Connor; Perry J Pickhardt; David H Kim; M Raquel Oliva; Stuart G Silverman
Journal:  AJR Am J Roentgenol       Date:  2011-07       Impact factor: 3.959

4.  Renal cell carcinoma: attenuation values on unenhanced CT.

Authors:  B Dustin Pooler; Perry J Pickhardt; Stacy D O'Connor; Richard J Bruce; Sutchin R Patel; Stephen Y Nakada
Journal:  AJR Am J Roentgenol       Date:  2012-05       Impact factor: 3.959

Review 5.  Expanding the morphologic spectrum of adult biphasic renal tumors--mixed epithelial and stromal tumor of the kidney with focal papillary renal cell carcinoma: case report and review of the literature.

Authors:  Kumaran M Mudaliar; Vikas Mehta; Gopal N Gupta; Maria M Picken
Journal:  Int J Surg Pathol       Date:  2013-05-27       Impact factor: 1.271

6.  Hybrid oncocytic/chromophobe renal cell tumours do not display genomic features of chromophobe renal cell carcinomas.

Authors:  Nicolas Poté; Annick Vieillefond; Jérôme Couturier; Sandrine Arrufat; Isabelle Metzger; Nicolas B Delongchamps; Philippe Camparo; Florence Mège-Lechevallier; Vincent Molinié; Mathilde Sibony
Journal:  Virchows Arch       Date:  2013-05-25       Impact factor: 4.064

7.  A case of liver metastasis from an oncocytoma with a focal area of chromophobe renal cell carcinoma: a wolf in sheep's clothing.

Authors:  Muhammad I Aslam; Laura Spencer; Guiseppe Garcea; Chris Pollard; Matthew S Metcalfe; Rebecca F Harrison; Ashley R Dennison
Journal:  Int J Surg Pathol       Date:  2008-05-21       Impact factor: 1.271

8.  Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes.

Authors:  Matthias Waldert; Tobias Klatte; Andrea Haitel; Mehmet Ozsoy; Joerg Schmidbauer; Michael Marberger; Mesut Remzi
Journal:  Eur Urol       Date:  2009-05-18       Impact factor: 20.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.